Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome

Trial Profile

Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Relacorilant (Primary)
  • Indications Cushing syndrome
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 22 Feb 2018 According to a Corcept Therapeutics media release, top-line results (n=17) (Low Dose Cohort) of this trial were published in a financial report.
    • 01 Aug 2017 According to a Corcept Therapeutics media release, results from this study are expected in the first quarter of 2018.
    • 30 Jan 2017 According to Corcept Therapeutics media release, results from this study are expected by the year-end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top